Compare JFIN & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | ORMP |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.7M | 165.3M |
| IPO Year | 2018 | 2010 |
| Metric | JFIN | ORMP |
|---|---|---|
| Price | $2.86 | $4.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 97.5K | ★ 470.5K |
| Earning Date | 06-03-2026 | 05-14-2026 |
| Dividend Yield | ★ 17.47% | 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 0.91 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $1.35 | $5.05 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $2.70 | $1.98 |
| 52 Week High | $18.70 | $5.19 |
| Indicator | JFIN | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 30.03 | 60.43 |
| Support Level | $2.70 | $3.69 |
| Resistance Level | $4.45 | $5.10 |
| Average True Range (ATR) | 0.29 | 0.32 |
| MACD | -0.06 | 0.08 |
| Stochastic Oscillator | 9.97 | 58.74 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.